Review Article
Potential Effects of Silymarin and Its Flavonolignan Components in Patients with β-Thalassemia Major: A Comprehensive Review in 2015
Table 1
Summary of carried-out randomized clinical trials of silymarin in patients with β-TM.
| Study author (reference) | Methods | Ferritin (ng/mL) | Groups |
Silymarin dose |
Study design |
Period of study (week) | Intervention group | Control group | P value between groups | Intervention () | Control () | Baseline | End | Baseline | End |
| Gharagozloo et al., 2009 [11] | DFO plus silymarin () | DFO plus placebo () | 40 mg/kg/day | Parallel | 12 | 4285.4 ± 2181.3 | 3548.3 ± 2012.8 | 3772.7 ± 1806.6 | 3727.8 ± 2025.0 | NS |
| Moayedi et al., 2013 [21] | DFO plus silymarin () | DFO plus placebo () | 40 mg/kg/day | Parallel | 36 | 3028.8 ± 2002.6 | 1972.2 ± 1250.6 | 1780.19 ± 1089.5 | 2213.8 ± 1375.1 | 0.01 |
| Gharagozloo et al., 2013 [3] | silymarin () | DFO plus silymarin () | 40 mg/kg/day | Parallel | 12 | NM | NM | NM | NM | — |
| Balouchi et al., 2014 [24] | DFO plus silymarin () | DFO plus placebo () | 40 mg/kg/day | Parallel | 24 | 2292.20 ± 1382.26 | 1935.70 ± 1649.35 | 1701.56 ± 773.51 | 1794.67 ± 870.65 | NS |
|
Hagag et al., 2013 [25] | DFX plus silymarin () | DFX plus placebo () | 40 mg/kg/day | Parallel | 24 | 3253.7 + 707.1 | 1067.2 + 297.9 | 3049.2 + 527.7 | 1795.3 + 551.6 | 0.001 |
|
Hagag et al., 2015 [22] | DFP plus silymarin () | DFP plus placebo () | 40 mg/kg/day | Parallel | 36 | 1901 + 563.38 | 989.5 + 178.57 | 1885.2 + 510.54 | 1260 + 212.26 | <0.001 |
|
|
NS: nonsignificant. NM: nonmeasured.
|